Archives of the
Turkish Society of Cardiology
Invited review - General

Clinical pharmacology of the apixaban and frequently asked questions about its clinical use

1.

Gazi Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara

Archives of the Turkish Society of Cardiology 2016; 44: Supplement 1-6
Read: 930 Downloads: 159 Published: 01 July 2021

Apixaban is a new, strong, reversible, competitive direct inhibitor of factor Xa. By inhibiting factor Xa, it prevents the conversion of prothrombin to thrombin. Large, randomized clinical trials showed that apixaban is superior to varfarin in the prevention of stroke in atrial fibrillation and caused less bleeding than varfarin. This article summarized clinical pharmacology of the apixaban and responded to frequently asked questions about it.

Files
TURKISH
ISSN 1016-5169 EISSN 1308-4488